Citations

Clear

371 citation(s) found for "Cho, B".

Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease
Díaz, Alejandro A. , Orejas, J. , Grumley, Scott , Nath, Hrudaya , Wang, Wei , Yen, Andrew , Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Sonavane, Sushilkumar K. , Washko, George R. , Estépar, Raúl San Jośe , San Jose Estepar, Raul , Diaz, Alejandro A , Dolliver, Wojciech Remington , Yen, Andrew, Aziz, Muhammad Usman , Estépar, R. San José , Kim, Victor, Make, Barry J. , Han, MeiLan King , Cho, Michael H.

Mayo Clinic

JAMA | May 21, 2023 | Volume: 329 | Issue: 21 | Pages: 1832

10.1001/jama.2023.2065 | PMID 37210745 Get It

Importance Airway mucus plugs are common in patients with chronic obstructive pulmonary disease (COPD); however, the association of airway mucus plugging and mortality in patients with COPD is unknown. Objective To determine whether airway mucus plugs identified on chest computed tomography (CT) were associated with increased all-cause mortality. Design, Setting, and Participants Observational retrospective analysis of prospectively collected data of patients with a diagnosis of COPD in the Genetic Epidemiology of COPD cohort. Participants were non-Hispanic Black or White individuals, aged 45 to 80 years, who smoked at least 10 pack-years. Participants were enrolled at 21 centers across the US between November 2007 and April 2011 and were followed up through August 31, 2022. Exposures Mucus plugs that completely occluded airways on chest CT scans, identified in medium- to large-sized airways (ie, approximately 2- to 10-mm lumen diameter) and categorized as affecting 0, 1 to 2, or 3 or more lung segments. Main Outcomes and Measures The primary outcome was all-cause mortality, assessed with proportional hazard regression analysis. Models were adjusted for age, sex, race and ethnicity, body mass index, pack-years smoked, current smoking status, forced expiratory volume in the first second of expiration, and CT measures of emphysema and airway disease. Results Among the 4483 participants with COPD, 4363 were included in the primary analysis (median age, 63 years [IQR, 57-70 years]; 44% were women). A total of 2585 (59.3%), 953 (21.8%), and 825 (18.9%) participants had mucus plugs in 0, 1 to 2, and 3 or more lung segments, respectively. During a median 9.5-year follow-up, 1769 participants (40.6%) died. The mortality rates were 34.0% (95% CI, 32.2%-35.8%), 46.7% (95% CI, 43.5%-49.9%), and 54.1% (95% CI, 50.7%-57.4%) in participants who had mucus plugs in 0, 1 to 2, and 3 or more lung segments, respectively. The presence of mucus plugs in 1 to 2 vs 0 and 3 or more vs 0 lung segments was associated with an adjusted hazard ratio of death of 1.15 (95% CI, 1.02-1.29) and 1.24 (95% CI, 1.10-1.41), respectively. Conclusions and Relevance In participants with COPD, the presence of mucus plugs that obstructed medium- to large-sized airways was associated with higher all-cause mortality compared with patients without mucus plugging on chest CT scans.
Association of neutrophil-to-lymphocyte ratio with clinical, pathological, radiological, laboratory features and disease outcomes of invasive breast cancer patients: A retrospective observational cohort study
Jadoon, Sarosh Khan , Soomro, Rufina , Khan, Raja Muhammad Ijaz , Iqbal, Sadia, Yasmin, Farah , Najeeb, Hala , Cho, Namiya, Resham, Hasan, Syeda Fatima Saba , Khalid, Muhammad Zain , Alvi, Sarosh , Rizvi, Ahsan Mujtaba, Asghar, Muhammad Sohaib , Ahsan, Muhammad Nadeem , Saleem, Nida , Shaikh, Taha Gul , Alvi, Sarosh , Rizvi, Ahsan Mujtaba

Mayo Clinic

Medicine | May 18, 2023 | Volume: 102 | Issue: 20 | Pages: e33811

10.1097/md.0000000000033811 | PMID 37335707 Get It

Inflammatory conditions play part in the progression of malignancies, and markers signifying growth of these factors can indicate prognosis. Neutrophil-to-lymphocyte (NLR) is used as a marker of subclinical inflammation that may become an integral part of workup to indicate prognosis and associated pathology. This study aims to explore the association of NLR ratio with clinical characteristics, radiological assessment and staging, histopathology, and disease outcomes of breast cancer. A retrospective cohort study was conducted in a tertiary care center to include breast cancer patients that were diagnosed between January 2001 and December 2020. Data including tumor size, lymph nodes, metastasis, histological grading, ER/PR/HER2-neu status, molecular subtypes, clinical staging); nodal findings (sentinel and axillary); pathology from frozen section; and disease outcomes were assessed. Multivariable regression and Kaplan–Meier survival curves were employed to indicate the association of NLR with breast cancer features and disease-free survival. A total of 2050 patients had a median age of 50 years, median NLR levels of 2.14, most common pathology ductal followed by lobular, and most common site of metastasis being lungs followed by bones. Disease-free rate was 7.6%, and a recurrence rate of 1.8%, while 1.6% deaths were reported. NLR was found associated with age, treatment outcomes, tumor size, lymph nodes, metastasis and clinical staging. Other positive correlations were with Ki67 proliferation index, molecular subtypes, and tumor size on frozen section (at transverse and craniocaudal dimensions). Negative correlations were seen with estrogen and progesterone receptors. However, NLR was not found predictable of disease-free survival (P = .160). Significant predictors of disease-free survival were histological grading, ER, PR status, molecular subtype, and Ki67 proliferation index. NLR being a readily available marker has shown novel findings in its association with tumor staging, disease outcomes and characteristics of breast malignancy.
Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility
Lindborg, Carter M., Mukaddam, Mona Al , Baujat, Geneviève , Cunto, Carmen L. De, Delai, Patricia , Haga, Nobuhiko , Morhart, Rolf, Ruiter, Ruben D. de , Scott, Christiaan , Pignolo, Robert J. , Al Mukaddam, Mona, Cho, Tae‐Joon , Cunto, Carmen De , Eekhoff, Elisabeth M. W. , Hsiao, Edward C. , Seemann, Petra , Szczepanek, Małgorzata, Tabarkiewicz, Jacek , Kaplan, Frederick S.

Mayo Clinic

Clinical Orthopaedics & Related Research | May 8, 2023 | Volume: 481 | Issue: 12 | Pages: 2447-2458

10.1097/corr.0000000000002672 | PMID 37156007 Get It

Abstract Background Fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disorder with episodic and progressive heterotopic ossification. Tissue trauma is a major risk factor for flareups, heterotopic ossification (HO), and loss of mobility in patients with FOP. The International Clinical Council on FOP generally recommends avoiding surgery in patients with FOP unless the situation is life-threatening, because soft tissue injury can trigger an FOP flareup. Surprisingly little is known about flareups, HO formation, and loss of mobility after fractures of the normotopic (occurring in the normal place, distinct from heterotopic) skeleton when treated nonoperatively in patients with FOP. Questions/purposes (1) What proportion of fractures had radiographic evidence of union (defined as radiographic evidence of healing at 6 weeks) or nonunion (defined as the radiographic absence of a bridging callus at 3 years after the fracture)? (2) What proportion of patients had clinical symptoms of an FOP flareup because of the fracture (defined by increased pain or swelling at the fracture site within several days after closed immobilization)? (3) What proportion of patients with fractures had radiographic evidence of HO? (4) What proportion of patients lost movement after a fracture? Methods We retrospectively identified 36 patients with FOP from five continents who sustained 48 fractures of the normotopic skeleton from January 2001 to February 2021, who were treated nonoperatively, and who were followed for a minimum of 18 months after the fracture and for as long as 20 years, depending on when they sustained their fracture during the study period. Five patients (seven fractures) were excluded from the analysis to minimize cotreatment bias because these patients were enrolled in palovarotene clinical trials (NCT02190747 and NCT03312634) at the time of their fractures. Thus, we analyzed 31 patients (13 male, 18 female, median age 22 years, range 5 to 57 years) who sustained 41 fractures of the normotopic skeleton that were treated nonoperatively. Patients were analyzed at a median follow-up of 6 years (range 18 months to 20 years), and none was lost to follow-up. Clinical records for each patient were reviewed by the referring physician–author and the following data for each fracture were recorded: biological sex, ACVR1 gene pathogenic variant, age at the time of fracture, fracture mechanism, fracture location, initial treatment modality, prednisone use at the time of the fracture as indicated in the FOP Treatment Guidelines for flare prevention (2 mg/kg once daily for 4 days), patient-reported flareups (episodic inflammatory lesions of muscle and deep soft connective tissue characterized variably by swelling, escalating pain, stiffness, and immobility) after the fracture, follow-up radiographs of the fracture if available, HO formation (yes or no) as a result of the fracture determined at a minimum of 6 weeks after the fracture, and patient-reported loss of motion at least 6 months after and as long as 20 years after the fracture. Postfracture radiographs were available in 76% (31 of 41) of fractures in 25 patients and were independently reviewed by the referring physician–author and senior author for radiographic criteria of fracture healing and HO. Results Radiographic healing was noted in 97% (30 of 31) of fractures at 6 weeks after the incident fracture. Painless nonunion was noted in one patient who sustained a displaced patellar fracture and HO. In seven percent (three of 41) of fractures, patients reported increased pain or swelling at or near the fracture site within several days after fracture immobilization that likely indicated a site-specific FOP flareup. The same three patients reported a residual loss of motion 1 year after the fracture compared with their prefracture status. HO developed in 10% (three of 31) of the fractures for which follow-up radiographs were available. Patient-reported loss of motion occurred in 10% (four of 41) of fractures. Two of the four patients reported noticeable loss of motion and the other two patients reported that the joint was completely immobile (ankylosis). Conclusion Most fractures treated nonoperatively in individuals with FOP healed with few flareups, little or no HO, and preservation of mobility, suggesting an uncoupling of fracture repair and HO, which are two inflammation-induced processes of endochondral ossification. These findings underscore the importance of considering nonoperative treatment for fractures in individuals with FOP. Physicians who treat fractures in patients with FOP should consult with a member of the International Clinical Council listed in the FOP Treatment Guidelines (https://www.iccfop.org). Level of Evidence Level IV, therapeutic study.
Upregulation of the ERRγ–VDAC1 axis underlies the molecular pathogenesis of pancreatitis
Chanda, Dipanjan , Thoudam, Themis , Sinam, Ibotombi Singh , Lim, Chae Won , Wang, Jiale , Lee, Kyeong‐Min , Ma, Jing , Saxena, Romil, Choi, Jinhyuk , Oh, Chang Joo , Lee, Hoyul , Jeon, Yong Hyun , Jung, Hoe‐Yune , Choi, Hueng‐Sik , Ji, Baoan , Liangpunsakul, Suthat , Lee, In‐Kyu , Wang, Jiale , Lee, Kyeong-Min , Ma, Jing , Oh, Chang Joo , Lee, Hoyul , Jung, Hoe-Yune , Choi, Hueng-Sik , Suh, Jae Myoung , Auwerx, Johan , Liangpunsakul, Suthat , Jeon, Jae-Han , Lee, In-Kyu , Kim, Myeongjin , Cho, Sung Jin , Park, Keun‐Gyu

Mayo Clinic

Proceedings of the National Academy of Sciences | May 8, 2023 | Volume: 120 | Issue: 20 | Pages: No page available

10.1073/pnas.2219644120 | PMID 37155882 Get It

Emerging evidence suggest that transcription factors play multiple roles in the development of pancreatitis, a necroinflammatory condition lacking specific therapy. Estrogen-related receptor γ (ERRγ), a pleiotropic transcription factor, has been reported to play a vital role in pancreatic acinar cell (PAC) homeostasis. However, the role of ERRγ in PAC dysfunction remains hitherto unknown. Here, we demonstrated in both mice models and human cohorts that pancreatitis is associated with an increase in ERRγ gene expression via activation of STAT3. Acinar-specific ERRγ haploinsufficiency or pharmacological inhibition of ERRγ significantly impaired the progression of pancreatitis both in vitro and in vivo. Using systematic transcriptomic analysis, we identified that voltage-dependent anion channel 1 (VDAC1) acts as a molecular mediator of ERRγ. Mechanistically, we showed that induction of ERRγ in cultured acinar cells and mouse pancreata enhanced VDAC1 expression by directly binding to specific site of the Vdac1 gene promoter and resulted in VDAC1 oligomerization. Notably, VDAC1, whose expression and oligomerization were dependent on ERRγ, modulates mitochondrial Ca 2+ and ROS levels. Inhibition of the ERRγ–VDAC1 axis could alleviate mitochondrial Ca 2+ accumulation, ROS formation and inhibit progression of pancreatitis. Using two different mouse models of pancreatitis, we showed that pharmacological blockade of ERRγ–VDAC1 pathway has therapeutic benefits in mitigating progression of pancreatitis. Likewise, using PRSS1 R122H -Tg mice to mimic human hereditary pancreatitis, we demonstrated that ERRγ inhibitor also alleviated pancreatitis. Our findings highlight the importance of ERRγ in pancreatitis progression and suggests its therapeutic intervention for prevention and treatment of pancreatitis.
Somatic Mutations of MUC5B Within Lung Tissue in Idiopathic Pulmonary Fibrosis
Khan, Mehnaz, Krone, Katie A. , Hobbs, B.D. , Hersh, C.P. , Barwick, Lucas, Flaherty, K.R., Brown, Kevin K. , Wise, R.A.A., Martinez, F.J., Silverman, E.K., DeMeo, Dawn L. , Cho, M.H., Bick, Alex, Yun, Jeong H. , Ghosh, Auyon , Castaldi, Peter J. , Miller, P., Sciurba, Frank C. , Limper, Andrew H. , Flaherty, K.R., Criner, Gerard J. , Cho, M.H.

Mayo Clinic

A16. INTERROGATING GENOMIC, TRANSCRIPTIONAL, AND EPIGENETIC MECHANISMS IN LUNG FIBROSIS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1036-A1036

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1036 Get It

Whole Genome Sequencing Analysis of Mucus Plugging in Chronic Obstructive Pulmonary Disease (COPD)
Medicine, Trans-Omics in Precision, Silverman, E.K., Nath, H.P., Orejas, J. , Yen, Andrew , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Sonavane, Sushilkumar K. , Cho, M.H. , Kim, Katherine Callaway , Grumley, Scott , Dolliver, Wojciech Remington , Yen, A., Aziz, Muhammad Usman , Díaz, Alejandro A.

Mayo Clinic

A24. COPD PHENOTYPES: LOOKING OUTSIDE THE LUNG | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1153-A1153

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1153 Get It

Airway Mucus Plugs and Chronic Obstructive Pulmonary Disease Exacerbations
Kim, V., Nath, H.P., Yen, A., Wang, Wei , Orejas, J. , Kligerman, Seth , Jacobs, Kathleen, Espinosa, C. Cano, Estebar, R. San Jose, Manapragada, Padma P. , Abozeed, Mostafa , Terry, Nina , Zahid, Mohd , Sonavane, Sushil, Cho, M.H. , Grumley, Scott , Dolliver, Wojciech Remington , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Díaz, Alejandro A.

Mayo Clinic

B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1 | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2858-A2858

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2858 Get It

Persistent Airway Mucus Plugs and Changes in Lung Function in COPD
Mettler, S.K., Nath, H.P., Orejas, J. , Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , DIAZ, ALEJANDRO A, Grumley, Scott , Dolliver, Wojciech Remington , Aziz, Muhammad Usman , Estépar, Raúl San Jośe

Mayo Clinic

B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1 | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2857-A2857

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2857 Get It

Silent Airway Mucus Plugs in COPD and Association With Disease Severity and Outcomes
Mettler, S.K., Nath, H.P., Orejas, J. , Yen, A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Dolliver, Wojciech Remington , Aziz, Muhammad Usman , Estépar, R. San José , Estépar, Raúl San Jośe , Díaz, Alejandro A.

Mayo Clinic

D92. NOVEL IMAGING AND PHYSIOLOGIC MEASURES IN COPD | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6542-A6542

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6542 Get It